News | News By Subject | News by Disease News By Date | Search News

Candidiasis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Approves Strativa Pharmaceuticals's Oravig(TM) Buccal Tablets for Treatment of Oropharyngeal Candidiasis     4/16/2010
Barrier Therapeutics, Inc. (BTRX) Announces Phase 3 Results For Hyphanox(TM) In Vaginal Candidiasis; Product Fails To Meet Primary Endpoint Of Non-Inferiority Versus Fluconazole     6/30/2005
Barrier Therapeutics, Inc. (BTRX) Receives Not Approvable Letter From The FDA For Zimycan(TM)     5/25/2005
Fujisawa Healthcare, Inc. And Roche (RHHBY) Announce Co-promotion Of MYCAMINE(TM)     3/31/2005
Fujisawa Healthcare, Inc. Release: Mycamine(TM) Receives FDA Approval     3/17/2005
Vicuron Pharmaceuticals, Inc. (MICU) Announces Phase 3 Trial Results Demonstrate Superiority Of Anidulafungin Versus Fluconazole In Invasive Candidiasis/Candidemia; Stocks Rise     2/7/2005
BioAlliance Pharma Announces Preliminary Phase III Data On Miconazole Lauriad Bioadhesive Buccal Tablets For Local Treatment Of Oropharyngeal Candidiasis In Head And Neck Cancer Patients Following Radiation Therapy     1/4/2005
Pfizer Inc.'s (PFE) Antifungal Medicine VFEND(R) Receives FDA Approval For Treatment Of Serious Bloodstream Infections Caused By Candida In Nonneutropenic Patients     12/28/2004
FDA Tells Vicuron Pharmaceuticals, Inc. (MICU) New Drug Data Needed, Shares Sink     5/24/2004
Pfizer Inc.'s (PFE) VFEND(R) Receives FDA Approval For Treatment Of Esophageal Candidiasis     11/17/2003

News from Around the Web

Press Releases
Viamet Presents Phase IIb Results Demonstrating Unprecedented Efficacy Of Oral VT-1161 In The Treatment Of Recurrent Vulvovaginal Candidiasis     6/5/2017
Viamet Reports Positive Results From REVIVE Phase 2b Trial Of Oral VT-1161 In Recurrent Vulvovaginal Candidiasis     1/6/2017
Cidara (CDTX) Completes Enrollment In Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical In Vulvovaginal Candidiasis     1/4/2017
Corvus Pharma Announces Preliminary Phase 1/1b Clinical Data With Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety And Evidence Of Anti-Tumor Activity As A Single Agent In Patients With Advanced Refractory Cancers     11/11/2016
Astellas Pharma US Provides Update On Phase 3 Study Evaluating Isavuconazole In Patients With Candidemia And Other Invasive Candida Infections     7/30/2015
AstraZeneca Canada (AZN) Release: PEGASUS-TIMI 54 Study Shows That Long-Term Treatment With BRILINTA Reduced Thrombotic Cardiovascular Events In Patients With A History Of Heart Attack     3/16/2015
FDA Accepts Par Pharmaceutical Companies, Inc. (PRX) Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis     8/19/2009
BioAlliance Pharma Completes Patient Enrolment Ahead of Schedule for Its Pivotal Phase III Clinical Trial of Loramyc® in The USA for the Treatment of Oropharyngeal Candidiasis     11/16/2007
BioDelivery Sciences International (BDSI) Announces FDA Acceptance Of Bioral(R) Amphotericin IND     2/2/2007
BioAlliance Pharma Release: FDA Allows IND For US Pivotal Phase III Trial     9/6/2005
Vicuron Pharmaceuticals, Inc. (MICU) Files New Drug Application (NDA) For Anidulafungin For Treatment Of Invasive Candidiasis/Candidemia     8/19/2005
BioAlliance Pharma: Files IND For US Pivotal Phase III Trial     7/21/2005
Vicuron Pharmaceuticals, Inc. (MICU) Files Amendment To Anidulafungin New Drug Application (NDA) For Treatment Of Esophageal Candidiasis     5/31/2005
BioAlliance Pharma Presents Results From Phase III Study Of Miconazole Lauriad Bioadhesive Buccal Tablets For Treatment Of Oropharyngeal Candidiasis In Head & Neck Cancer Patients     5/17/2005
Astellas Pharma Inc. Release: Anti-Fungal Agent MYCAMINE(TM) Available To Physicians     5/13/2005